Andrew D. Luber

Dr. Luber serves as President and Chief Executive Officer for Virion Therapeutics, LLC. He is a clinical pharmacist with over 20+ years of experience in drug development and clinical research. As Executive Director of Research for both Pacific Oaks Medical Group and Tower ID Research in Los Angeles, CA, Dr. Luber was a clinical investigator in more than 70 clinical trials, including 4 Phase 1a/b studies. His most recent experience was as Vice President, Clinical Pharmacology for Moerae Matrix, Inc. helping to advance a novel anti-fibrotic and anti-inflammatory peptide into human clinical trials. Dr. Luber has authored numerous textbook chapters and articles in peer-reviewed journals, as well as online resources in the area of HIV Pharmacology and Pharmacokinetics. He authored the American Academy of HIV Medicine's (AAHIVM) Self-Directed Study Guide’s Pharmacology and Pharmacokinetic sections. In addition, he was a core faculty member in the development of The Viral Hepatitis Mid-Level Provider Certification Program for the American Association for Study of Liver Diseases (AASLD). Dr. Luber has worked with many different pharmaceutical and biotechnology companies as a clinical study investigator, speakers bureau presenter, steering committee and advisory board member, as well as serving as a clinical consultant to both large and early stage pharmaceutical companies.

Dr. Luber received his B.S. Pharm and Pharm.D. from Temple University School of Pharmacy, Philadelphia PA. He completed his residency in both pharmacy practice and infectious diseases, as well his research fellowship in infectious diseases pharmacotherapy, at the University of California, San Francisco, School of Pharmacy, San Francisco, California.